Surrogate markers are essential indices for the evaluation of treatment in a chronic, long-term, variably progressing illness like HIV infection. The major immunologic hallmarks of HIV infection are immune deficiency, immune activation, and specific immune response to HIV antigens. These have been related to the pathogenesis of HIV disease and to prognosis. The studies proposed here are directed at relating these immunologic surrogate markers to the effects of anti-retroviral and immune-based therapies (such as lymphokines, cytokine blockers and vaccines) and to treatment efficacy in ACTG protocols. Quantitative measurement of immune deficiency and activation will be done by three-color flow cytometry characterizing CD4 T cells, CD8 T cells, B cells, and NK cells. Functional assessments will include measurements of proliferation and cytotoxicity, as well as specific suppressor molecules. Levels of soluble serum markers and individual cytokines will be used to assess immune activation. Specific cell-mediated immunity will be tested by cytotoxicity against target cells expressing HIV proteins, which will be a critical immunologic marker for evaluation of vaccine trials as well as other treatment protocols in HIV-seropositive patients. The Developmental Immunology Research Program will work in conjunction with the Adult ACTU Core Program at UCLA and other institutions and SDAC to carry out these studies. Analysis are planned to compare effects of zidovudine, ddl and ddC and other compounds as they are developed. Data will be compared with CD4 (and CD8) T cell levels and p24 antigen and other virologic markers measured in associated studies. Surrogate markers will be evaluated to determine if a marker is changed by therapy, the maximum and duration of change and range of responses observed in HIV-infected persons. Also, surrogate markers will be compared head-to-head to determine whether they make distinctive or similar contributions to AIDS treatment evaluation. We will determine if additional surrogate markers can improve existing criteria indicating need for therapy. It is anticipated that eventually a small panel of surrogate markers will be able to provide essential and rapid evaluation of new agents, administration schedules and drug combinations.

Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Kempen, John H; Sugar, Elizabeth A; Varma, Rohit et al. (2014) Risk of cataract among subjects with acquired immune deficiency syndrome free of ocular opportunistic infections. Ophthalmology 121:2317-24
Kozak, Igor; Vaidya, Vijay; Van Natta, Mark L et al. (2014) The prevalence and incidence of epiretinal membranes in eyes with inactive extramacular CMV retinitis. Invest Ophthalmol Vis Sci 55:4304-12
Jabs, Douglas A; Ahuja, Alka; Van Natta, Mark et al. (2013) Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 120:1262-70
Wohl, David A; Kendall, Michelle A; Feinberg, Judith et al. (2013) The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One 8:e78676
Gangaputra, Sapna; Drye, Lea; Vaidya, Vijay et al. (2013) Non-cytomegalovirus ocular opportunistic infections in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 155:206-212.e5
Ribaudo, Heather J; Smith, Kimberly Y; Robbins, Gregory K et al. (2013) Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis. Clin Infect Dis 57:1607-17
Kempen, John H; Sugar, Elizabeth A; Lyon, Alice T et al. (2012) Risk of cataract in persons with cytomegalovirus retinitis and the acquired immune deficiency syndrome. Ophthalmology 119:2343-50
Gangaputra, Sapna; Kalyani, Partho S; Fawzi, Amani A et al. (2012) Retinal vessel caliber among people with acquired immunodeficiency syndrome: relationships with disease-associated factors and mortality. Am J Ophthalmol 153:434-444.e1
Kalyani, Partho S; Fawzi, Amani A; Gangaputra, Sapna et al. (2012) Retinal vessel caliber among people with acquired immunodeficiency syndrome: relationships with visual function. Am J Ophthalmol 153:428-433.e1
Kalyani, Partho S; Holland, Gary N; Fawzi, Amani A et al. (2012) Association between retinal nerve fiber layer thickness and abnormalities of vision in people with human immunodeficiency virus infection. Am J Ophthalmol 153:734-42, 742.e1

Showing the most recent 10 out of 126 publications